Modality
Gene Editing
MOA
KIF18Ai
Target
GPRC5D
Pathway
Epigenetic
IPFLN
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
Aug 2018
→ Jul 2031
Phase 1Current
NCT03777617
1,226 pts·IPF
2023-12→2027-02·Terminated
NCT08668935
1,653 pts·LN
2018-08→2031-07·Active
2,879 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-02-1511mo awayPh2 Data· IPF
2031-07-175.3y awayPh2 Data· LN
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Active
P1/2
Termina…
Catalysts
Ph2 Data
2027-02-15 · 11mo away
IPF
Ph2 Data
2031-07-17 · 5.3y away
LN
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03777617 | Phase 1/2 | IPF | Terminated | 1226 | PASI75 |
| NCT08668935 | Phase 1/2 | LN | Active | 1653 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D |